What question did this study set out to answer?

To evaluate the potential of Suzetrigine as a treatment for refractory trigeminal neuralgia.

June 4, 2026

Use of Suzetrigine for Treatment of Refractory Trigeminal Neuralgia in Four Patients: A Small Case Series

Puntos clave

To evaluate the potential of Suzetrigine as a treatment for refractory trigeminal neuralgia.
Descriptive case series of four patients with refractory trigeminal neuralgia.
Each patient had previously failed standard pharmacological and interventional treatments.
Suzetrigine was administered, and symptom improvements were monitored.
All four patients exhibited notable symptomatic improvements with Suzetrigine treatment.
No adverse effects were reported during the treatment period.
Findings suggest that NaV1.8 could be a viable target for trigeminal neuralgia treatment.

Resumen

Suzetrigine selectively blocks the NaV1.8 voltage-gated sodium channel in peripheral neurons. Trigeminal neuralgia (TN) is a neuropathic pain syndrome affecting the trigeminal nerve and is traditionally treated with nonselective sodium channel blockers. No studies have evaluated Suzetrigine for TN, but potential involvement of NaV1.8 in TN signaling may represent a novel therapeutic target. We describe four patients with varying symptomatology of TN and previously failed responses to pharmacological and interventional treatments who exhibited notable symptomatic improvements with Suzetrigine, with no adverse effects. Further study is required in larger populations regarding the safety and efficacy of long-term Suzetrigine use for refractory TN.

Preguntar a la IA

Me gusta

Guardar